[Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
OBJECTIVE
To evaluate the significance of the combined assay of chromogranin A (CgA) and prostate specific antigen (PSA) in the diagnosis of prostate cancer.


METHODS
Serum CgA and PSA were detected by ELISA technique in 55 cases of prostate cancer (PCa), 25 cases of benign prostate hyperplasia (BPH), and 50 cases of normal subjects (control).


RESULTS
The serum CgA level in the PCa group was significantly higher than those in the control and BPH groups (P < 0.05), and increased with clinical stages. The parallel and serial tests associated with serum PSA and CgA raised the rate of detection of prostate cancer.


CONCLUSIONS
The combined assay of serum PSA and CgA is of significant clinical value in raising the rate of diagnosis of prostate cancer, as well as in staging and prognosing the disease.
Sun
Chang-Cheng
CC
Department of Urology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China. suncc379@163.com
Zheng
Wei
W
Kong
Chui-Ze
CZ
Wang
Xia
X
Yang
Chun-Ming
CM
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D053379:Chromogranin A / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D053379:Chromogranin A; D017430:Prostate-Specific Antigen